Huonslab

Huonslab Co, Ltd, a subsidiary of Huons Global Co, Ltd, South Korea (KOSDAQ: 084110), was established in 2018 under the leadership of Huons Group Chairman Sung Tae Yoon. Huonslab is dedicated to advancing biologics research and development with a pioneering spirit. Central to its mission is the development of innovative drug delivery technologies such as hydiffuze for universal antibody Sub-Q delivery. With a robust pipeline that includes HLB3-002, a lead drug candidate in pre-IND stage, and ongoing non-clinical developments in Alzheimer's, Obesity, and Diabetes, Huonslab exemplifies a commitment to addressing unmet medical needs of patients. Huons Global Co, Ltd, the parent company, is a publicly traded holding company listed on the KOSDAQ since 2006, encompassing 11 subsidiaries specialized in Bio, Pharmaceuticals, and Healthcare. With over 2,200 employees worldwide, Huons Global has demonstrated consistent corporate profitability, achieving a 19-year Compound Annual Growth Rate (CAGR) of 19%. In 2023, Huons Global reported approximately $583 million in sales revenue, marking a 14% increase from the previous year, and an operating profit of approximately $88 million, a 33% rise year-over-year. This performance underscores Huons Global's position as a leader in the Pharmaceuticals industry, driven by innovation, strategic growth, and inventing solutions for human medications.